Medical policy: Bioimpedance Devices for Detection and Management of Lymphedema

Policy number: MP 2.190

Effective date: 9/1/2026

Policy

Bioimpedance spectroscopy may be considered medically necessary to confirm a diagnosis of lymphedema in the following clinical scenario:

• The individual is asymptomatic with history of surgery, radiotherapy, or trauma impacting the lymphatic system, and testing would guide decisions regarding early intervention (e.g., physical therapy, complete decongestive therapy).

Bioimpedance spectroscopy may be considered medically necessary for surveillance of lymphedema in the following clinical scenarios:

• The individual is asymptomatic with history of surgery, radiotherapy, or trauma impacting the lymphatic system, and testing would guide decisions regarding early intervention (e.g., physical therapy, complete decongestive therapy); OR
• The individual remains symptomatic following a course of conservative therapy for lymphedema, and testing would guide decisions regarding escalation of therapy (e.g., liposuction, surgery) (see Policy Guidelines).

Bioimpedance spectroscopy is considered investigational outside of the aforementioned clinical scenarios. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Policy guidelines

National Comprehensive Cancer Network Guidelines for Survivorship (Version 2.2026)

“Early detection and diagnosis are key for optimal lymphedema management, because stages 0 and 1 are reversible, whereas stages 2 and 3 are less responsive to treatment. Therefore, survivors at risk for lymphedema should be regularly screened for lymphedema by symptom assessment, clinical exam, and validated volumetric tools and/or tools that measure extracellular fluid to identify early signs of lymphedema; tools may include bioimpedance spectroscopy. If baseline measurements are not available, emphasis should be on incorporating clinical exam and symptom assessment with objective measurements using the unaffected limb as a reference.”

“When possible, pretreatment baseline objective measurements should be obtained for patients with treatment-related or individual risk factors. Validated volumetric tools, such as perometry, 3D camera or tape measure/girth measures (which may be converted to volumetric measures), and/or tools that measure extracellular fluid, such as bioimpedance spectroscopy, are recommended.”

The NCCN outline the stages of lymphedema as follows:

• Stage 0 (latent/subclinical): Lymphatic dysfunction without swelling; subtle symptoms, such as a feeling of heaviness or fatigue in the limb, may be present.
• Stage 1 (spontaneously reversible): Accumulation of fluid and protein causing swelling; pitting edema may be evident; increased girth, heaviness, and/or stiffness of affected area. For the limbs, swelling is relieved with elevation.
• Stage 2 (irreversible): Spongy tissue consistency, with pitting edema that becomes less evident as swelling increases; tissue fibrosis causing hardness and increase in size. For the limbs, swelling is not relieved with elevation.
• Stage 3 (lymphostatic elephantiasis): Severe dry, scaly, thickened skin; increased swelling and girth of affected area; can be debilitating. In the limbs, fluid leakage and blisters are common. Fungal infection and papilloma may occur. Pitting can be absent due to progressive deposition of fat and fibrosis, which is the hallmark of later stage lymphedema.

National Comprehensive Cancer Network Guidelines for Breast Cancer (Version 2.2026)

“Lymphedema is a potential side effect after the treatment of axillary lymph node surgery resulting from damage to the lymphatic system. Early detection/diagnosis of lymphedema is key for optimal management. Consider pretreatment measurement of both arms as a baseline for patients with risk factors for lymphedema.”

National Lymphedema Network

Screening and Measurement for Early Detection of Breast Cancer Related Lymphedema: “Circumferential tape measurements are acceptable when made with a flexible, non-elastic Gulick II (or similar) tape measure. (6) At minimum, six measurements are recommended: circumference at the mid-hand, wrist, elbow, upper arm just below the axilla, and at 10cm distal to and proximal to the lateral epicondyle on both arms. Bioelectrical spectroscopy (BIS) or infrared perometry are suggested as alternative or adjunct methods to circumferential measurement. Specific protocols describing standard positions and measurements for these procedures should be in place”

American Physical Therapy Association

“Bioimpedance analysis should be used to detect lymphatic transport impairments and diagnose subclinical and early-stage lymphedema in patients at risk for breast cancer–related lymphedema (Stage 0 and 1).”

Evidence Quality: Level II reliability, validity, and diagnostic accuracy; Recommendation Strength: Grade B”

Cross-reference:

• MP 6.013 Pneumatic Compression Devices for the Treatment of Lymphedema and Venous Insufficiency

Product variations

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO - Refer to FEP Medical Policy Manual.

Description/Background

Lymphedema

Lymphedema is an accumulation of fluid due to disruption of lymphatic drainage. Lymphedema can be caused by congenital or inherited abnormalities in the lymphatic system (primary lymphedema) but is most often caused by acquired damage to the lymphatic system (secondary lymphedema), often as a result cancer treatment. Survivors who had surgery, radiation, or chemoradiation to the axillary, supraclavicular, cervical, or pelvic inguinal lymph node system are at risk for the development of lymphedema. Sentinel node biopsy also increases the risk of lymphedema, although it poses less risk than complete dissection. A BMI ≥30 kg/m2, localized infection, increased number of nodes removed, and higher initial extent of disease raise the risk of lymphedema development.

Diagnosis

A diagnosis of secondary lymphedema is based on history (e.g., cancer treatment, trauma) and physical examination (localized, progressive edema, and asymmetric limb measurements) when other causes of edema can be excluded. Imaging, such as MRI, computed tomography, ultrasound, or lymphoscintigraphy, may be used to differentiate lymphedema from other causes of edema in diagnostically challenging cases.

Management and Treatment

Lymphedema is treated using elevation, compression, and exercise. Conservative therapy may consist of several features depending on the severity of the lymphedema. Patients are educated on the importance of self-care including hygienic practices to prevent infection, maintaining ideal body weight through diet and exercise, and limb elevation. Compression therapy consists of repeatedly applying padding and bandages or compression garments. Manual lymphatic drainage is a light pressure massage performed by trained physical therapists or by patients designed to move fluid from obstructed areas into functioning lymph vessels and lymph nodes. Complete decongestive therapy is a multiphase treatment program involving all of the previously mentioned conservative treatment components at different intensities. Pneumatic compression pumps may also be considered as an adjunct to conservative therapy or as an alternative to self-manual lymphatic drainage in patients who have difficulty performing self-manual lymphatic drainage. In patients with more advanced lymphedema after fat deposition and tissue fibrosis has occurred, palliative surgery using reductive techniques such as liposuction may be performed.

Bioimpedance Spectroscopy

Bioimpedance spectroscopy is based on the theory that the level of opposition to flow of electric current (impedance) through the body is inversely proportional to the volume of fluid in the tissue. In lymphedema, with the accumulation of excess interstitial fluid, tissue impedance decreases.

Bioimpedance has been proposed as a diagnostic test for this condition. In usual care, lymphedema is recognized clinically or via limb measurements. However, management via bioelectrical impedance spectroscopy has been proposed as a way to implement early treatment of subclinical lymphedema to potentially reduce its severity.

Regulatory Status

Devices that have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process to aid in the assessment of lymphedema are summarized in Table 1. These include the SOZO (K180126), MoistureMeterD (K143310), and ImpediMed L-Dex™ U400 (K050415).

Table 1. FDA Cleared Bioimpedance Spectroscopy Devices for Lymphedema

FDA product code: OBH.

Rationale

Summary of evidence

For individuals who have known or suspected lymphedema who receive bioimpedance spectroscopy, the evidence includes a systematic review, one RCT, prospective comparative observational studies, and multiple uncontrolled observational studies. The relevant outcomes are test validity, symptoms, and quality of life. Results from the PREVENT trial compared bioimpedance with standard tape measure following treatment for breast cancer. At a median follow up of 32.9 months, BIS patients triggered intervention at a lower rate than tape measured patients (20.1% vs 27.5%) and fewer patients progressed in this group (7.9% vs 19.2%). The RCT was limited by its open label design and lack of reporting on important health outcomes. The single prospective comparative study found a significantly lower rate of clinical lymphedema in patients managed with bioimpedance devices but had several limitations, including nonrandomized design, lack of blinding, lack of complete data on a substantial proportion of enrolled patients, and lack of a systematic method for diagnosing lymphedema in the control group. Retrospective studies suggested that postoperative bioimpedance monitoring is feasible but provide limited information about its efficacy. As more studies emerge, there may be stronger evidence to suggest the benefits of this technology. With the recently published results of the PREVENT trial and current societal guidance, there is sufficient evidence to determine the positive effects of the technology on health outcomes.

Definitions

N/A

Disclaimer

Capital Blue Cross’ medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member’s benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the member’s benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross’ Provider Services or Member Services.

Coding information

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Medically necessary

References

1. DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. May 2013; 14(6): 500-15. PMID 23540561
2. International Society of Lymphology Executive Committee. The Diagnosis and Treatment of Peripheral Lymphedema: 2016 Consensus Document of the International Society of Lymphology. 2016;
3. Pusic AL, Cemal Y, Albornoz C, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv. Mar 2013; 7(1): 83-92. PMID 23212603
4. Oremus M, Walker K, Dayes I, et al. Technology Assessment: Diagnosis and treatment of secondary lymphedema. Rockville, MD: Agency for Healthcare Research and Quality; 2010.
5. Cornish BH, Chapman M, Hirst C, et al. Early diagnosis of lymphedema using multiple frequency bioimpedance. Lymphology. Mar 2001; 34(1): 2-11. PMID 11307661
6. Hayes S, Janda M, Cornish B, et al. Lymphedema secondary to breast cancer: how choice of measure influences diagnosis, prevalence, and identifiable risk factors. Lymphology. Mar 2008; 41(1): 18-28. PMID 18581955
7. Barrio AV, Eaton A, Frazier TG. A Prospective Validation Study of Bioimpedance with Volume Displacement in Early-Stage Breast Cancer Patients at Risk for Lymphedema. Ann Surg Oncol. Dec 2015; 22 Suppl 3: S370-5. PMID 26085222
8. Blaney JM, McCollum G, Lorimer J, et al. Prospective surveillance of breast cancer-related lymphedema in the first-year post-surgery: feasibility and comparison of screening measures. Support Care Cancer. Jun 2015; 23(6): 1549-59. PMID 25398360
9. Ridner SH, Dietrich MS, Cowher MS, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. Ann Surg Oncol. Oct 2019; 26(10): 3250-3259. PMID 31054038
10. Soran A, Ozmen T, McGuire KP, et al. The importance of detection of subclinical lymphedema for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection; a prospective observational study. Lymphat Res Biol. Dec 2014; 12(4): 289-94. PMID 25495384
11. Laidley A, Anglin B. The Impact of L-Dex (R) Measurements in Assessing Breast Cancer-Related Lymphedema as Part of Routine Clinical Practice. Front Oncol. 2016; 6: 192. PMID 27656420
12. Koelmeyer LA, Borotkanics RJ, Alcorso J, et al. Early surveillance is associated with less incidence and severity of breast cancer-related lymphedema compared to a traditional referral model of care. Cancer. Mar 15 2019; 125(6): 854-862. PMID 30521080
13. Kilgore LJ, Korentager SS, Hangge AN, et al. Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions. Ann Surg Oncol. Oct 2018; 25(10): 2948-2952. PMID 29987599
14. Whitworth PW, Cooper A. Reducing chronic breast cancer-related lymphedema utilizing a program of prospective surveillance with bioimpedance spectroscopy. Breast J. Jan 2018; 24(1): 62-65. PMID 29063664
15. Erdogan Iyigun Z, Selamoglu D, Alco G, et al. Bioelectrical impedance for detecting and monitoring lymphedema in patients with breast cancer. Preliminary results of the florence nightingale breast study group. Lymphat Res Biol. Mar 2015; 13(1): 40-5. PMID 25526543
16. Shah C, Vicini F, Beitsch P, et al. The use of bioimpedance spectroscopy to monitor therapeutic intervention in patients treated for breast cancer related lymphedema. Lymphology. Dec 2013; 46(4): 184-92. PMID 25141461
17. Lim SM, Han Y, Kim SI, et al. Utilization of bioelectrical impedance analysis for detection of lymphedema in breast Cancer survivors: a prospective cross sectional study. BMC Cancer. Jul 08 2019; 19(1): 669. PMID 31286884
18. Kaufman DI, Shah C, Vicini FA, et al. Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema. Breast Cancer Res Treat. Dec 2017; 166(3): 809-815. PMID 28831632
19. Whitworth PW, Shah C, Vicini F, et al. Preventing Breast Cancer-Related Lymphedema in High-Risk Patients: The Impact of a Structured Surveillance Protocol Using Bioimpedance Spectroscopy. Front Oncol. 2018; 8: 197. PMID 29946531
20. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Survivorship. Version 2.2026.
21. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026.
22. National Lymphedema Network Medical Advisory Committee. April 2011. Screening and Early Detection of Breast Cancer Related Lymphedema: The Imperative.
23. O'Donnell TF Jr, Allison GM, Iafrati MD. A systematic review of guidelines for lymphedema and the need for contemporary intersocietal guidelines for management of lymphedema. J Vasc Surg Venous Lymphat Disord. 2020;8(4):676-684. doi:10.1016/j.jvsv.2020.03.006 PMID 32444277
24. Shah C, Whitworth P, Valente S, et al. Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: clinical practice guidelines. Breast Cancer Res Treat. 2023;198(1):1-9. doi:10.1007/s10549-022-06850-7 PMID 36566297
25. Spitz JA, Chao AH, Peterson DM, Subramanian V, Prakash S, Skoracki RJ. Bioimpedance spectroscopy is not associated with a clinical diagnosis of breast cancer-related lymphedema. Lymphology. 2019;52(3):134-142. PMID 31874125
26. Forte AJ, Huayllani MT, Boczar D, et al. Use of bioimpedance spectroscopy for prospective surveillance and early diagnosis of breast cancer-related lymphedema. Breast Dis. 2021;40(2):85-93. doi:10.3233/BD-201008 PMID 33646139
27. Levenhagen K, Davies C, Perdomo M, Ryans K, Gilchrist L. Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline From the Oncology Section of the American Physical Therapy Association. Phys Ther. 2017;97(7):729-745. PMID: 28838217
28. Ridner SH, Dietrich MS, Boyages J, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphat Res Biol. 2022;20(6):618-628. PMID: 35099283
29. Boyages J, Vicini FA, Mamav B, et al. Axillary Treatment and Chronic Breast Cancer-Related Lymphedema: Implications for Prospective Surveillance and Intervention From a Randomized Controlled Trial. JCO Oncol Pract. 2023;19(12):1116-1124.